Skip to main content

Table 4 Time to progression (TTP) according to biomarkers expression considered as per clinical practicea

From: Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?

  No. HR (95% CI)b Median TTP, months (95% CI) p
AR status
  < 1% 17 1.00 12.0 (4.3-48.1)  
  ≥ 1% 85 0.96 (0.56-1.66) 16.1 (13.0-19.0) 0.884
  < 10% 26 1.00 13.8 (11.0-42.1)  
  ≥ 10% 76 0.98 (0.61-1.57) 16.0 (13.0-19.0) 0.935
AR/ER ratio
  < 0.90 (best cutoff) 52 1.00 12.9 (11.0-17.1)  
  ≥ 0.90 (best cutoff) 50 0.83 (0.55-1.24) 18.0 (14.0-24.6) 0.362
AR/PgR ratio
  < 0.96 (best cutoff) 34 1.00 16.8 (12.1-47.9)  
  ≥ 0.96 (best cutoff) 68 1.65 (1.05-2.61) 16.0 (12.4-19.0) 0.028
PgR status
  < 1% 22 1.00 10.5 (4.0-17.0)  
  ≥ 1% 80 2.18 (1.34-3.55) 17.0 (14.0-24.7) 0.001
Ki67 status
  < 20% 63 1.00 17.6 (14.8-22.1)  
  ≥ 20% 38 1.60 (1.05-2.45) 12.0 (8.2-16.1) 0.028
HER2 status
 negative 88 1.00 15.8 (12.9-19.0)  
 positive 14 1.15 (0.65-2.02) 18.0 (7.0-46.0) 0.929
  1. Abbreviations: ER estrogen receptor, PgR progesterone receptor, AR androgen receptor, HER2 human epidermal growth factor receptor 2
  2. abiomarker measured on metastatic sample when a metastatic biopsy was available, or on primary tumor when biopsy of metastasis had not been performed
  3. bHR hazard ratio